All Articles

TWFG just secured a $125M credit facility. It's not just about money; it's a strategic move to accelerate acquisitions and pioneer an AI-driven future for insurance.

Grandstand's new Rollcard aims to be the go-to debit card for high rollers, but this fintech pivot is a high-stakes bet on navigating a minefield of regulatory risks.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

The Chinese robotics firm posted record revenue but a staggering $5.6M loss. Is this a strategic masterstroke or a reckless bet on a future that may never pay off?

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

dLocal posts a stunning 92% surge in payment volume, cementing its emerging market dominance. Yet, a closer look at profitability reveals a complex balancing act.

With $4.4M in new funding, Clarity Systems is deploying AI scanners to see inside returns, fighting fraud without penalizing honest shoppers.

Intellicheck posts record Q2 revenue and a fifth straight profitable quarter, but a key client's pivot to a multi-vendor model tests its diversification strategy.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

With regulatory winds at its back in the US and EU, Cibus is pushing to commercialize its non-GMO tech. Can new leadership turn R&D into revenue before cash runs out?

Don't let headline numbers fool you. True North's Q2 reveals a 7.1% NOI surge and 96% occupancy, a testament to its sharp portfolio management.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

Plunging revenues and a staggering net loss push IM Cannabis to the edge, forcing a desperate and bizarre strategic pivot from medical marijuana to military drones.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

Soluna Holdings reports a 145% revenue surge but a widening net loss, revealing a bold strategy to trade short-term profits for a vast green AI infrastructure.

Freeman Gold's new feasibility study reveals a $1B+ valuation for its Idaho project, but can it navigate the path from blueprint to bullion in a volatile market?

After years of losses, Smith Micro's Q2 results show a dramatic improvement in profitability, driven by deep cost cuts and a strategic shift beyond carriers.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

Brandon Hall Group's 2026 HCM Excellence Awards spotlight the firms winning the war for talent. Here's why investors should pay attention to these benchmarks.